Drug Trial Radar · NCT03716427
Drug Interaction Study of CT1812 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Nov 10, 2016
Primary completion
Dec 27, 2016
Study completion Feb 15, 2017
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).
Conditions
- Healthy Volunteers
Interventions
CT1812Drug
tolbutamideDrug
Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
dextromethorphanDrug
Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
OmeprazoleDrug
Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
midazolamDrug
Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma-concentration time curve of CT1812 (Day 6) compared to the baseline values (Day -2)Time frame: 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jasper Clinic
Kalamazoo, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.